Schering Aktiengesellschaft

Institut National De La Sante Et De La Recherche Medicale

Societe Civile Bioprojet

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Bioproject

Schering Aktiengesellchaft

Schering Aktiensgesellschaft

Bayer Pharma Aktiengesellschaft

Ralph Lipp

Jean-Charles Schwartz

Walter Schunack

Monique Garbarg

Jean-Michel Arrang

Wolfgang Heil

Jeanne-Marie Lecomte

Jutta Riedl

Thomas Backensfeld

Holger Stark

Katja Purand

Wasyl Tertiuk

Abdellatif Fkyerat

Charon R Ganellin

Henry Laurent

Peter Esperling

Johannes Wilhelm Tack

Johannes-Wilhelm Tack

Torsten Wagner

Clemens Gunther

Ulrich Tauber

Werner Skuballa

Helmut Dahl

Adrian Funke

Heinrich Michel

Renate Heithecker

Bernd Iffert

Clements Gunther

Susanne Keitel

J&uuml;rgen Westermann

Martin Wessel

Juergen Hilman

Michael Huempel

Ulf Tistam

Methods for improving solubility and bioavailability of lipophilic compounds are described. Particularly, described are stabilized supersaturated solid solutions, particularly in power from, of lipophilic drugs, such as steroidal molecules.

Stabilised supersaturated solids of lipophilic drugs

Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and &#x3b2;-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.

Compositions of estrogen-cyclodextrin complexes

This invention relates to a quick-release tablet formulation with &#x3e;99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.

Oral fludara of high-purity formulation with quick release of active ingredient

Cyclodextrin-drospirenone inclusion complexes

Pharmaceutical composition for use as a contraceptive

The invention relates to the use of an oxidation inhibitor, i.e. active carbon, for ambient air in industrial manufacturing, especially in the processing of prostane derivatives, whereby the oxidation inhibitor removes ozone from the process air before contact with said prostane derivatives. The concentration of decomposition products is reduced.

Oxidation inhibitors in prostane derivatives

A compound selected from the group consisting of a compound of the formula

Imidazole compounds and their therapeutic applications

3-Oxyiminopregnane-21-carbolactones of formula I,

Oxyiminopregnancarbolactones

Low-dosed steroid tablets that contain gallic acid ester as an

Transdermal therapeutic systems that contain sex steroids and dimethyl

Agent for transdermal administration that contains gestodene esters

A compound selected from the group consisting of a compound of the formula ##STR1## having antagonist properties to histamine H.sub.3 -receptors.

Imidazole derivatives for pharmaceutical use

A transdermal therapeutic system is described, which is characterized in that it contains a crystallization inhibitor and optionally penetration enhancer in an active ingredient-containing adhesive matrix.

Transdermal therapeutic systems with crystallization inhibitors

Growing community of inventors

Berlin, Germany

Ralph Lipp